Lisdexamfetamine
Centrally Acting Sympathomimetics
- Drug class
- Centrally Acting Sympathomimetics
- Availability
- Prescription only
- Routes
- Oral
- Markets covered
- 2
- Products on record
- 29
Overview
Lisdexamfetamine is an active pharmaceutical ingredient in the Centrally Acting Sympathomimetics group (N06BA). The information below is compiled per regulator from the product labels on record, with direct links to the original documents.
Regulatory status by market
| Market | Regulator | Products | Last revision |
|---|---|---|---|
| GB United Kingdom | MHRA | 27 | May 22, 2026 |
| US United States | FDA | 2 | March 16, 2026 |
GBUnited Kingdom· MHRA
27 products
Uses
Lisdexamfetamine is indicated as part of a comprehensive treatment programme for attention deficit/hyperactivity disorder (ADHD) in children aged 6 years and over when response to previous methylphenidate treatment is considered clinically inadequate.
Lisdexamfetamine is also indicated as part of a comprehensive treatment programme for attention deficit/hyperactivity disorder (ADHD) in adults with pre-existing symptoms of ADHD in childhood. Treatment must be under the supervision of a specialist in childhood and/or adolescent behavioural disorders (for paediatric patients) or a specialist in behavioural disorders (for adult patients).
Diagnosis should be be based on a complete history and evaluation of the patient according to current DSM criteria or ICD guidelines. Diagnosis cannot be made solely on the presence of one or more symptoms. In adults, the presence of pre-existing symptoms of ADHD in childhood is required and should be confirmed retrospectively (according to the patient’s medical record or, if not available, through appropriate and structured instruments or interviews).
USUnited States· FDA
2 products
Uses
2) ] . 4 ) Lisdexamfetamine dimesylate capsules are not indicated for weight loss. Use of other sympathomimetic drugs for weight loss has been associated with serious cardiovascular adverse events. 4) ] . Lisdexamfetamine dimesylate capsules are not indicated or recommended for weight loss.
Use of other sympathomimetic drugs for weight loss has been associated with serious cardiovascular adverse events. 2) ] .
How to take
Drug interactions
Known interactions involving Lisdexamfetamine. Select one for details. This list is informational and not a complete interaction checker.
Showing 240 of 306. Type above to find a specific drug.
Interaction data compiled from DDInter (academic, CC-BY). Severity classification only - this is not a complete interaction checker and not medical advice.
Sources & citations
- [1]MHRA (UK) · PL002400604 · revised April 17, 2026
- [2]FDA DailyMed · 0e024b69-567c-4b… · revised November 3, 2025 [PDF]
Information on this page is compiled from public regulatory records. Drugvu is not affiliated with any regulator or pharmaceutical manufacturer. This is not medical advice. Always consult a qualified healthcare professional.